Excitatory Amino Acid Antagonists
"Excitatory Amino Acid Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists.
| Descriptor ID |
D018691
|
| MeSH Number(s) |
D27.505.519.625.190.300 D27.505.696.577.190.300
|
| Concept/Terms |
Excitatory Amino Acid Antagonists- Excitatory Amino Acid Antagonists
- Antagonists, Excitatory Amino Acid
- Amino Acids, Excitatory, Antagonists
- Glutamate Receptor Antagonists
- Antagonists, Glutamate Receptor
- Receptor Antagonists, Glutamate
- EAA Antagonists
- Antagonists, EAA
- Glutamate Antagonists
- Antagonists, Glutamate
- Amino Acid Antagonists, Excitatory
|
Below are MeSH descriptors whose meaning is more general than "Excitatory Amino Acid Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Excitatory Amino Acid Antagonists".
This graph shows the total number of publications written about "Excitatory Amino Acid Antagonists" by people in this website by year, and whether "Excitatory Amino Acid Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 3 | 5 |
| 2018 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Excitatory Amino Acid Antagonists" by people in Profiles.
-
"Remote Monitoring of Intranasal Ketamine Self-Administration as Maintenance Therapy in Treatment-Resistant Depression (TRD): A Novel Strategy for Vulnerable and At-Risk Populations to COVID-19?" Am J Geriatr Psychiatry. 2020 08; 28(8):892-893.
-
Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis. Can J Neurol Sci. 2018 11; 45(6):652-659.
-
Alzheimer disease: Non-pharmacological and pharmacological management of cognition and neuropsychiatric symptoms. Australas Psychiatry. 2018 Aug; 26(4):358-365.
-
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Int J Environ Res Public Health. 2018 04 17; 15(4).
-
Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res. 2018 09; 199:313-318.
-
Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neurons during status epilepticus. Neurobiol Dis. 2017 Jul; 103:45-53.
-
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 2017 03 21; 7(3):e1065.
-
Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders. Dialogues Clin Neurosci. 2017 03; 19(1):27-36.
-
Fibromyalgia and bipolar disorder: extent of comorbidity and therapeutic implications. J Biol Regul Homeost Agents. 2017 Jan-Mar; 31(1):17-20.
-
MK-801-Treated Oligodendrocytes as a Cellular Model to Study Schizophrenia. Adv Exp Med Biol. 2017; 974:269-277.